Aurora Cannabis Expands Medical Portfolio in Australia and New Zealand
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy ACB?
Aurora Cannabis is expanding its Aurora medical portfolio in Australia and New Zealand, delivering patients and prescribers enhanced choice, reliable quality, and easier access to science-backed products. The expansion underscores the company's ongoing dedication to meeting the unique needs of patients and healthcare professionals in the region, reflecting Aurora's strategic focus on long-term global growth. The expansion in New Zealand this month includes two new THC flower products - Big Wave, Night Ride, as well as the balanced strain, Half Moon coming soon in Q1 FY27. The brand will also debut four new resin cartridges in Australia this month including, Chemango Kush, Cosmic Cream, Lunar Express, and Soul Train Haze.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACB
Wall Street analysts forecast ACB stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.360
Low
6.28
Averages
6.77
High
7.39
Current: 3.360
Low
6.28
Averages
6.77
High
7.39
About ACB
Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company’s segments include Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, IndiMed and CraftPlant. The Company also holds a 50.1% controlling interest in Bevo Farms Ltd., a supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aurora Expands Product Line in Australia and New Zealand
- Market Expansion Strategy: Aurora Cannabis is launching new products in Australia and New Zealand, including two THC flower products and four resin cartridges, aimed at meeting the needs of patients and prescribers for high-quality medical cannabis, thereby enhancing its leadership position in international markets.
- Product Diversification: The introduction of Big Wave™ and Night Ride™ in New Zealand, along with the upcoming Half Moon™ product, showcases Aurora's ongoing commitment to product innovation, which is expected to enhance patient choice and experience, further solidifying market share.
- Quality Assurance: All new products are derived from Aurora's proprietary genetics and manufactured in EU-GMP and TGA-GMP certified facilities, ensuring safety and high quality, which enhances customer trust and brand loyalty.
- Long-term Investment Commitment: Aurora has pledged to continue investing in the Australian and New Zealand markets to support the evolving needs of patients, reflecting the company's strategic focus on global growth, which is anticipated to drive future business expansion and revenue growth.
See More
Cannabis Sector Update: Aurora's Strategic Shift Amid Record Medical Sales
- Aurora Financial Performance: Aurora Cannabis reported net revenue of $94.2 million for Q3 2026, a 7% year-over-year increase, with global medical cannabis sales reaching $76.2 million, accounting for over 80% of total sales, indicating strong growth potential in the high-margin medical market.
- Strategic Transformation Plan: Aurora announced plans to gradually exit select Canadian consumer cannabis markets to reduce sales and marketing costs, which is expected to significantly improve overall profit margins in the coming quarters.
- Canopy Growth Results: Canopy Growth reported net revenue of $90.4 million for Q3 2026, with a nearly 50% reduction in net loss despite weak international performance, reflecting positive progress in cost control and market integration.
- Cronos Brand Expansion: Cronos Group launched its premium Lord Jones brand in Israel, marking a significant step in its global expansion strategy aimed at meeting local market demands with high-quality products while enhancing brand recognition in international markets.
See More
Aurora Cannabis Q3 2026 Revenue Beats Expectations Despite Income Drop
- Revenue Performance: Aurora Cannabis reported Q3 2026 revenue that exceeded expectations, although adjusted net income fell to approximately $7.2 million year-over-year, indicating potential for revenue growth but challenges in profitability.
- Rising Costs: The company's adjusted SG&A expenses rose to $35.8 million in the quarter, compared to $31.3 million in FY25 Q3, putting pressure on profits and impacting overall financial performance.
- Strategic Shift: Aurora has made a strategic decision to focus resources on the global medical cannabis market, aiming to address current market challenges and seize growth opportunities in the medical sector, which could yield higher returns in the future.
- Market Reaction: Despite the revenue beat, Aurora's shares fell approximately 9% in Wednesday trading, reflecting investor concerns over declining profitability, which may affect future investor confidence.
See More
Aurora Cannabis Launches New $100M At-the-Market Offering
- Offering Program Initiated: Aurora Cannabis has filed a prospectus supplement to establish a new at-the-market offering program to issue up to $100 million in common shares, aimed at enhancing the company's liquidity for future strategic investments.
- Clear Use of Proceeds: The net proceeds from this offering will be allocated for increased cultivation capacity and M&A activities, indicating the company's proactive strategic positioning to expand market share and enhance competitiveness.
- Positive Market Reaction: The launch of this financing program is expected to boost investor confidence, potentially driving the company's stock price upward and laying a foundation for future growth.
- International Sales Growth: Aurora Cannabis reported strong international sales in Q2 2026, demonstrating its expansion potential in global markets, further justifying the need for this financing initiative.
See More
Aurora Cannabis Reports Strong International Sales for Q2 2026
- International Sales Growth: Aurora Cannabis reported significant growth in international sales for Q2 2026, reflecting the positive impact of its global expansion strategy, which enhances its competitive position in the international cannabis market.
- High-Margin Medical Cannabis: The growth in high-margin medical cannabis sales indicates sustained demand for its products in the premium market, which is expected to further drive overall revenue growth and improve profitability.
- Strong Financial Performance: The financial report from Aurora Cannabis shows that sales exceeded market expectations in the second quarter, indicating ongoing improvements in cost control and operational efficiency, which boosts investor confidence.
- Optimistic Market Outlook: With the expansion into international markets and growth in high-margin product lines, the future development prospects for Aurora Cannabis are widely regarded as positive, likely attracting more investor interest in its long-term growth potential.
See More
Aurora Cannabis Reports Strong Q3 2026 Financial Results
- Record Revenue: Aurora Cannabis achieved a net revenue of CAD 94.2 million in Q3 2026, a 7% increase from the previous year, with the medical cannabis segment contributing CAD 76.2 million, highlighting the company's strong growth potential in the global medical cannabis market.
- Adjusted EBITDA Performance: Adjusted EBITDA stood at CAD 18.5 million, showing a slight decline from the previous year, yet reflecting the company's ongoing investments in high-margin businesses and improved operational efficiencies.
- Improved Cash Flow: Free cash flow reached CAD 15.5 million, significantly improving compared to the previous year, indicating the company's success in cost control and operational optimization, thereby enhancing its capacity for future investments.
- Strategic Focus Shift: Aurora has decided to exit lower-margin consumer cannabis markets to concentrate resources on the higher-margin medical cannabis business, which is expected to further enhance overall gross margins and adjusted SG&A expenses, strengthening its competitive position in the market.
See More
Aurora Expands Product Line in Australia and New Zealand
- Market Expansion Strategy: Aurora Cannabis is launching new products in Australia and New Zealand, including two THC flower products and four resin cartridges, aimed at meeting the needs of patients and prescribers for high-quality medical cannabis, thereby enhancing its leadership position in international markets.
- Product Diversification: The introduction of Big Wave™ and Night Ride™ in New Zealand, along with the upcoming Half Moon™ product, showcases Aurora's ongoing commitment to product innovation, which is expected to enhance patient choice and experience, further solidifying market share.
- Quality Assurance: All new products are derived from Aurora's proprietary genetics and manufactured in EU-GMP and TGA-GMP certified facilities, ensuring safety and high quality, which enhances customer trust and brand loyalty.
- Long-term Investment Commitment: Aurora has pledged to continue investing in the Australian and New Zealand markets to support the evolving needs of patients, reflecting the company's strategic focus on global growth, which is anticipated to drive future business expansion and revenue growth.
See More
Cannabis Sector Update: Aurora's Strategic Shift Amid Record Medical Sales
- Aurora Financial Performance: Aurora Cannabis reported net revenue of $94.2 million for Q3 2026, a 7% year-over-year increase, with global medical cannabis sales reaching $76.2 million, accounting for over 80% of total sales, indicating strong growth potential in the high-margin medical market.
- Strategic Transformation Plan: Aurora announced plans to gradually exit select Canadian consumer cannabis markets to reduce sales and marketing costs, which is expected to significantly improve overall profit margins in the coming quarters.
- Canopy Growth Results: Canopy Growth reported net revenue of $90.4 million for Q3 2026, with a nearly 50% reduction in net loss despite weak international performance, reflecting positive progress in cost control and market integration.
- Cronos Brand Expansion: Cronos Group launched its premium Lord Jones brand in Israel, marking a significant step in its global expansion strategy aimed at meeting local market demands with high-quality products while enhancing brand recognition in international markets.
See More
Aurora Cannabis Q3 2026 Revenue Beats Expectations Despite Income Drop
- Revenue Performance: Aurora Cannabis reported Q3 2026 revenue that exceeded expectations, although adjusted net income fell to approximately $7.2 million year-over-year, indicating potential for revenue growth but challenges in profitability.
- Rising Costs: The company's adjusted SG&A expenses rose to $35.8 million in the quarter, compared to $31.3 million in FY25 Q3, putting pressure on profits and impacting overall financial performance.
- Strategic Shift: Aurora has made a strategic decision to focus resources on the global medical cannabis market, aiming to address current market challenges and seize growth opportunities in the medical sector, which could yield higher returns in the future.
- Market Reaction: Despite the revenue beat, Aurora's shares fell approximately 9% in Wednesday trading, reflecting investor concerns over declining profitability, which may affect future investor confidence.
See More
Aurora Cannabis Launches New $100M At-the-Market Offering
- Offering Program Initiated: Aurora Cannabis has filed a prospectus supplement to establish a new at-the-market offering program to issue up to $100 million in common shares, aimed at enhancing the company's liquidity for future strategic investments.
- Clear Use of Proceeds: The net proceeds from this offering will be allocated for increased cultivation capacity and M&A activities, indicating the company's proactive strategic positioning to expand market share and enhance competitiveness.
- Positive Market Reaction: The launch of this financing program is expected to boost investor confidence, potentially driving the company's stock price upward and laying a foundation for future growth.
- International Sales Growth: Aurora Cannabis reported strong international sales in Q2 2026, demonstrating its expansion potential in global markets, further justifying the need for this financing initiative.
See More
Aurora Cannabis Reports Strong International Sales for Q2 2026
- International Sales Growth: Aurora Cannabis reported significant growth in international sales for Q2 2026, reflecting the positive impact of its global expansion strategy, which enhances its competitive position in the international cannabis market.
- High-Margin Medical Cannabis: The growth in high-margin medical cannabis sales indicates sustained demand for its products in the premium market, which is expected to further drive overall revenue growth and improve profitability.
- Strong Financial Performance: The financial report from Aurora Cannabis shows that sales exceeded market expectations in the second quarter, indicating ongoing improvements in cost control and operational efficiency, which boosts investor confidence.
- Optimistic Market Outlook: With the expansion into international markets and growth in high-margin product lines, the future development prospects for Aurora Cannabis are widely regarded as positive, likely attracting more investor interest in its long-term growth potential.
See More
Aurora Cannabis Reports Strong Q3 2026 Financial Results
- Record Revenue: Aurora Cannabis achieved a net revenue of CAD 94.2 million in Q3 2026, a 7% increase from the previous year, with the medical cannabis segment contributing CAD 76.2 million, highlighting the company's strong growth potential in the global medical cannabis market.
- Adjusted EBITDA Performance: Adjusted EBITDA stood at CAD 18.5 million, showing a slight decline from the previous year, yet reflecting the company's ongoing investments in high-margin businesses and improved operational efficiencies.
- Improved Cash Flow: Free cash flow reached CAD 15.5 million, significantly improving compared to the previous year, indicating the company's success in cost control and operational optimization, thereby enhancing its capacity for future investments.
- Strategic Focus Shift: Aurora has decided to exit lower-margin consumer cannabis markets to concentrate resources on the higher-margin medical cannabis business, which is expected to further enhance overall gross margins and adjusted SG&A expenses, strengthening its competitive position in the market.
See More
